Contineum Therapeutics In... (CTNM)
NASDAQ: CTNM
· Real-Time Price · USD
7.60
0.22 (2.98%)
At close: Aug 18, 2025, 10:46 AM
Contineum Therapeutics Class A Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
Revenue | n/a | n/a | n/a | n/a | n/a | 50M | 50M | 50M | 50M | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | 42K | 115K | 196K | 196K | 154K | 81K |
Gross Profit | n/a | n/a | n/a | n/a | n/a | 49.96M | 49.88M | 49.8M | 49.8M | -154K | -81K |
Operating Income | 35.76M | 42.71M | 50.89M | -43.52M | -38.62M | 11.26M | 16.08M | 20.3M | 28.37M | -10.56M | -5.45M |
Interest Income | 9.55M | 9.52M | 8.91M | 8.17M | 7.16M | 5.84M | 4.61M | 3.16M | 1.42M | 743K | 342K |
Pretax Income | -56.86M | -49.83M | -42.26M | -35.62M | -31.73M | 19.58M | 23.17M | 23.59M | 29.96M | -12.34M | -7.51M |
Net Income | -56.86M | -49.83M | -42.26M | -35.46M | -31.45M | 19.13M | 22.72M | 22.98M | 29.23M | -12.34M | -7.51M |
Selling & General & Admin | 15.52M | 14.72M | 12.47M | 10.11M | 8.43M | 6.99M | 6.32M | 6.36M | 4.79M | 3.19M | 1.71M |
Research & Development | 50.52M | 44.36M | 38.42M | 33.42M | 30.19M | 31.75M | 27.6M | 23.55M | 17.05M | 7.59M | 3.95M |
Other Expenses | -101.79M | -101.79M | -101.79M | n/a | n/a | n/a | n/a | -10K | -10K | -10K | -10K |
Operating Expenses | -35.76M | -42.71M | -50.89M | 43.52M | 38.62M | 38.74M | 33.92M | 29.61M | 21.55M | 10.48M | 5.37M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 116K | 208K | 309K | 309K | 193K | 101K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 213K | 213K | 213K | 213K |
Cost & Expenses | -53.66M | -42.71M | -50.89M | 43.52M | 38.62M | 38.74M | 33.92M | 29.7M | 21.63M | 10.56M | 5.45M |
Income Tax Expense | n/a | n/a | n/a | -161K | -279K | 450K | 450K | 611K | 729K | n/a | n/a |
Shares Outstanding (Basic) | 25.9M | 25.87M | 25.85M | 25.73M | 25.72M | 25.72M | 25.13M | 25.43M | 25.72M | 25.72M | 25.13M |
Shares Outstanding (Diluted) | 25.9M | 25.87M | 25.85M | 25.73M | 25.72M | 25.72M | 25.13M | 25.43M | 25.72M | 25.72M | 25.13M |
EPS (Basic) | -2.29 | -2.02 | -1.73 | -1.39 | -1.24 | 0.73 | 0.87 | 0.88 | 1.13 | -0.49 | -0.3 |
EPS (Diluted) | -2.29 | -2.02 | -1.73 | -1.39 | -1.24 | 0.73 | 0.87 | 0.88 | 1.13 | -0.49 | -0.3 |
EBITDA | -60.63M | -51.68M | -43.51M | -36.92M | -33.04M | 18.36M | 23.57M | 24.14M | 30.46M | -11.99M | -7.33M |
EBIT | -42.94M | -51.95M | -43.77M | -37.14M | -33.24M | 18.18M | 23.38M | 23.9M | 30.27M | -12.14M | -7.41M |
Depreciation & Amortization | 215K | 275K | 258K | 220K | 201K | 183K | 195K | 239K | 196K | 154K | 81K |